Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncologist. 2010;15(6):627-35. doi: 10.1634/theoncologist.2010-0093. Epub 2010 May 17.

Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma.

Author information

1
UCL Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, U.K. s.strauss@ucl.ac.uk

Abstract

Detection of micrometastatic tumor cells in the bone marrow or peripheral blood of patients with Ewing family of tumors (EFTs) and osteosarcoma has been shown to correlate with poor outcome. Although one of the aims of chemotherapy is eradication of micrometastatic disease, these cells vary phenotypically from primary tumor cells and appear to be more resistant to chemotherapy. As a barrier to metastasis, cells normally undergo a form of cell death termed anoikis after they lose contact with the extracellular matrix or neighboring cells. Tumor cells that acquire malignant potential have developed mechanisms to resist anoikis and thereby survive after detachment from their primary site and while traveling through the circulation. Investigating mechanisms of resistance to anoikis, therefore, provides a valuable model to investigate regulation of micrometastatic disease. This review focuses on the current understanding of the mechanisms involved in mediating cell survival and resistance to anoikis in EFTs and osteosarcoma and discusses future studies that may help to identify novel therapeutics targeted at micrometastatic disease.

PMID:
20479280
PMCID:
PMC3227993
DOI:
10.1634/theoncologist.2010-0093
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center